Autopsy report · NCT01581060

Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours

“Study terminated for business reasons”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 1 month before it stopped.
• 41 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Heidelberg Pharma AG

Sponsor type

Industry

Conditions

Advanced Solid Tumours

Interventions

WX-554

Participants

41

Sites

5

Countries

United Kingdom

Trials that died the same way

• Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
  “Study terminated due to business decision” (92% match in meaning)
• TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
  “Study terminated for strategic business reasons” (91% match in meaning)
• A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
  “Study terminated due to business priorities” (91% match in meaning)
• Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
  “Study terminated due to business and strategic decision.” (90% match in meaning)
• Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
  “The study was terminated due to a business decision.” (89% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.